These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 12630184)
1. Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation. Datta D; McNamee M Conn Med; 2003 Jan; 67(1):11-2. PubMed ID: 12630184 [TBL] [Abstract][Full Text] [Related]
2. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. De Backer D Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539 [TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results. Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514 [TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440 [TBL] [Abstract][Full Text] [Related]
5. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. McCoy C; Matthews SJ Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504 [TBL] [Abstract][Full Text] [Related]
6. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis. Scipione MR; Nogid B; Davanos E; DiGregorio RV Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886 [TBL] [Abstract][Full Text] [Related]
7. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Micek ST; Isakow W; Shannon W; Kollef MH Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recombinant human activated protein C for severe sepsis. Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ; N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Kanji S; Devlin JW; Piekos KA; Racine E Pharmacotherapy; 2001 Nov; 21(11):1389-402. PubMed ID: 11714212 [TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (activated) in the treatment of severe sepsis. Vincent JL Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934 [TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa: a role in emergency department treatment of severe sepsis? McLeay AM Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720 [TBL] [Abstract][Full Text] [Related]
12. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Machała W; Wachowicz N; Komorowska A; Gaszyński W Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511 [TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) in an infant with gram-negative septic shock. Sajan I; Da-Silva SS; Dellinger RP J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755 [TBL] [Abstract][Full Text] [Related]
14. New and emerging therapies for sepsis. Healy DP Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516 [TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Weiss KD Pediatrics; 2004 Jan; 113(1 Pt 1):134. PubMed ID: 14702464 [No Abstract] [Full Text] [Related]
17. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma. Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957 [TBL] [Abstract][Full Text] [Related]
18. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715 [TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alpha (activated): the treatment for severe sepsis? Vincent JL Expert Opin Biol Ther; 2007 Nov; 7(11):1763-77. PubMed ID: 17961098 [TBL] [Abstract][Full Text] [Related]
20. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series. Berkman S; Weimert NA; Taber DJ; Baillie GM; Lin A; Baliga P; Chavin KD Transpl Infect Dis; 2009 Jun; 11(3):269-76. PubMed ID: 19392728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]